Literature DB >> 29053485

The Effects of Electroconvulsive Therapy Augmentation of Antipsychotic Treatment on Cognitive Functions in Patients With Treatment-Resistant Schizophrenia.

Bjanka Vuksan Ćusa, Nataša Klepac, Nenad Jakšić, Zoran Bradaš, Marija Božičević, Natalia Palac, Marina Šagud.   

Abstract

OBJECTIVES: Treatment-resistant schizophrenia (TRS) continues to be a challenge in modern psychiatry. Most of these patients have severe neurocognitive deficits. Electroconvulsive therapy (ECT) has proved effective and safe in the treatment of TRS, but because of potential neurocognitive adverse effects, it is associated with many controversies. The aim of this prospective, open study was to evaluate the effects of ECT augmentation of antipsychotics on cognitive functions in patients with TRS.
METHODS: Overall, 31 inpatients with TRS were included, 16 men, with an average (SD) age of 34.1 (11.187) years. The evaluation of clinical symptoms and global impression, as well as verbal memory, visual memory, working memory, psychomotor speed, verbal fluency, and executive functioning, was conducted before and after the completion of ECT treatment.
RESULTS: We ran a series of paired-samples t tests, and the Bonferroni adjustment for multiple comparisons reduced the significance level to P = 0.004. The neurocognitive domains that demonstrated statistically significant improvement were immediate and delayed verbal memory, and executive functioning, whereas statistical trend was observed for visual memory and psychomotor speed. None of the neurocognitive functions exhibited significant deterioration after the ECT treatment. Electroconvulsive therapy was effective in reducing general symptoms of schizophrenia, resulting in more than 30% decrease in the overall symptom severity measured by the Positive and Negative Syndrome Scale.
CONCLUSIONS: Notwithstanding some limitations of this study, the combination of ECT and antipsychotics has improved several neurocognitive domains, without evidence of worsening of any cognitive functions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29053485     DOI: 10.1097/YCT.0000000000000463

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  6 in total

Review 1.  Electroconvulsive Therapy and Schizophrenia: A Systematic Review.

Authors:  Sana A Ali; Nandita Mathur; Anil K Malhotra; Raphael J Braga
Journal:  Mol Neuropsychiatry       Date:  2019-04-02

Review 2.  Device-Based Modulation of Neurocircuits as a Therapeutic for Psychiatric Disorders.

Authors:  Zhi-De Deng; Bruce Luber; Nicholas L Balderston; Melbaliz Velez Afanador; Michelle M Noh; Jeena Thomas; William C Altekruse; Shannon L Exley; Shriya Awasthi; Sarah H Lisanby
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-01-06       Impact factor: 13.820

3.  A prospective multicenter assessor-blinded randomized controlled study to compare the efficacy of short versus long protocols of electroconvulsive therapy as an augmentation strategy to clozapine in patients with ultra-resistant schizophrenia (SURECT study).

Authors:  Virginie Moulier; Mohamed Wassim Krir; Marine Dalmont; Olivier Guillin; Maud Rothärmel
Journal:  Trials       Date:  2021-04-15       Impact factor: 2.279

Review 4.  Psychiatric Illness in Takotsubo (Stress) Cardiomyopathy: A Review.

Authors:  Arash Nayeri; Eric Rafla-Yuan; Srikanth Krishnan; Boback Ziaeian; Martin Cadeiras; John A McPherson; Quinn S Wells
Journal:  Psychosomatics       Date:  2018-02-02       Impact factor: 2.386

5.  Nature and Correlates of Executive Dysfunction in Schizophrenia: An Exploratory Study.

Authors:  Joseph Noel; Shonima A Viswanathan; Anju Kuruvilla
Journal:  Indian J Psychol Med       Date:  2020-08-10

6.  Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 Polymorphisms and Treatment Resistance in Schizophrenia.

Authors:  Marina Sagud; Lucija Tudor; Suzana Uzun; Matea Nikolac Perkovic; Maja Zivkovic; Marcela Konjevod; Oliver Kozumplik; Bjanka Vuksan Cusa; Dubravka Svob Strac; Iva Rados; Ninoslav Mimica; Alma Mihaljevic Peles; Gordana Nedic Erjavec; Nela Pivac
Journal:  Front Pharmacol       Date:  2018-07-03       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.